- Name: Xu Li
- Title: Professor and Chief Physician
- Email: xuli@sysucc.org.cn
- Phone:
Dr. Xu is currently a Professor and Chief Physician in the Department of Liver Surgery at Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China. She specializes in surgical oncology, and is good at the strategy of multidisciplinary treatment for liver cancer, as well as designing and conducting clinical trials. Her interests include the precise treatment of liver cancer, and translational research on biomarkers to predict therapeutic effect. She has published more than 60 peer-reviewed papers, including some in renowned journals such as Journal of Clinical Oncology, Journal of Hepatology, Hepatology, and Clinical Cancer Research. Dr. Xu also pays close attention to subject protection and ethical issues in clinical research, and serves as an Ethics Committee member of SYSUCC since 2014.
Liver cancer
Sep 2014~Aug 2015
The Johns Hopkins University Post doc Research Fellow
Jun 2007~Aug 2007
University of Michigan Visiting Scholar
Sep 2003~Jun 2006
Sun Yat-sen University Medical Doctor Degree in Oncology
Sep 1997~Jun 2000
Sun Yat-sen University of Medical Science Master Degree in Oncology
Sep 1992~Jun 1997
Sun Yat-sen University of Medical Science Bachelor Degree in Clinical Medical Science
Publications (first/co-first#/corresponding author*):
(1) High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma. Sun W#, Li SC#, Xu L#, Zhong W, Wang ZG, Pan CZ, Li J, Jin GZ, Ta N, Dong W, Liu D, Liu H, Ding J*, Wang HY. Clin Cancer Res 2020.
(2) Vessels that encapsulate tumor clusters (VETC) pattern is a predictor of sorafenib benefit in patientswith hepatocellular carcinoma. Fang JH#, Xu L#, Shang LR, Pan CZ, Ding J, Tang YQ, Liu H, Liu CX, Zheng JL, Zhang YJ, Zhou ZG, Xu J, Zheng LM, Chen MS*, Zhuang SM*. Hepatology 2019.
(3) A randomized controlled trial on patients withor without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC*, Li SP*, Lau WY. OncoImmunology 2016.
(4) Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Hepatobiliary Surg Nutr 2016.
(5) Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Xu L, Peng ZW, Chen MS*, Shi M, Zhang YJ, Guo RP, Lin XJ, Lau WY. J Hepatol 2015.
(6) Antiviral therapy improves survival of patients with hepatitis B virus-related hepatocellular carcinoma who treated with sorafenib. Xu L, Gao HJ, Huang JT, Wang HY, Zhou ZG, Zhang YJ, Li SP, and Chen MS*. J Gastroenterol Hepatol 2015.
(7) CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. Li L#, Xu L#, Yan J, Zhen ZJ, Ji Y, Liu CQ, Lau WY, Zheng LM*, Xu J*. J Exp Clin Cancer Res 2015.
(8) MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Zhang JP#, Zeng C#, Xu L#, Gong J, Fang JH, and Zhuang SM*. Oncogene. 2014
Updated May 2020 by International Office, Sun Yat-sen University Cancer Center